J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.
Zhitong FinanceApr 20 00:40
Vigil Neuroscience Analyst Ratings
BenzingaApr 20 00:32
J.P. Morgan Securities: The Vigil Neuroscience (VIGL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $23.00.
Zhitong FinanceApr 19 01:40
Vigil Neuroscience Analyst Ratings
BenzingaApr 19 01:37
JMP Securities Reiterates Market Outperform on Vigil Neuroscience, Maintains $23 Price Target
BenzingaApr 19 01:39
Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts
TipRanksMar 29 16:27
Vigil Neuroscience Analyst Ratings
BenzingaMar 27 21:22
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)
TipRanksMar 27 19:30
Buy Rating Affirmed: Vigil Neuroscience's Advancing TREM2 Programs and Strong Financial Position
TipRanksMar 27 01:05
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating
MT NewswiresMar 26 23:53
Stifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)
TipRanksFeb 9 21:29
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)
TipRanksJan 4 13:20
Morgan Stanley Downgrades Vigil Neuroscience to Underweight, Lowers Price Target to $4
BenzingaDec 19, 2023 22:31
Vigil Neuroscience Analyst Ratings
BenzingaDec 19, 2023 22:29
Promising Clinical Trial Results and Safety Profile Bolster Buy Rating for Vigil Neuroscience Inc: An In-depth Analysis
TipRanksNov 22, 2023 19:47
Wedbush Reiterates Outperform on Vigil Neuroscience, Maintains $23 Price Target
BenzingaNov 17, 2023 22:07
Vigil Neuroscience Analyst Ratings
BenzingaNov 17, 2023 22:06
Analysts Conflicted on These Healthcare Names: Vigil Neuroscience Inc (VIGL), Medicine Man Technologies (OtherSHWZ) and BioLife Solutions (BLFS)
TipRanksNov 17, 2023 20:31
Promising IGNITE Trial Results Bolster Buy Rating for Vigil Neuroscience Inc: An Analysis of VGL101's Potential in ALSP Treatment
TipRanksNov 17, 2023 13:35
Vigil Neuroscience's Robust Growth Potential: A Buy Recommendation Based on Innovative Pipeline and Anticipated Phase 2 IGNITE Study Results
TipRanksNov 14, 2023 15:18
No Data
No Data